BJL
TEVA icon

Brighton Jones LLC’s Teva Pharmaceuticals TEVA Stock Holding History

Brighton Jones LLC’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-6,073
Closed -$238K – 177
2013
Q2 		$238K Buy
+6,073
New +$237K 0.07% 104

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Brighton Jones LLC's TEVA Position: Q3 2013 in Review

Brighton Jones LLC sold out of Teva Pharmaceuticals (TEVA) in Q3 2013, closing a stake of 6,073 shares — an estimated $238K sold.

Brighton Jones LLC first reported a position in TEVA in Q2 2013 and held it in 1 quarter. The position peaked at $238K in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

  • Brighton Jones LLC reported no remaining Teva Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Brighton Jones LLC sold 6,073 Teva Pharmaceuticals shares in Q3 2013, an estimated $238K.
  • Brighton Jones LLC first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Brighton Jones LLC's Teva Pharmaceuticals position peaked at $238K in Q2 2013.
  • 705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Brighton Jones LLC's 13F filing for Q3 2013, filed 5 Nov 2013.